Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $252,284 - $565,381
2,038 Added 13.65%
16,965 $3.82 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $1.4 Million - $2.14 Million
14,927 New
14,927 $1.89 Million
Q4 2021

Feb 14, 2022

SELL
$110.64 - $159.4 $1.1 Million - $1.58 Million
-9,906 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$101.2 - $125.87 $1 Million - $1.25 Million
9,906 New
9,906 $1.21 Million
Q2 2021

Aug 16, 2021

SELL
$107.45 - $135.95 $298,603 - $377,805
-2,779 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$95.46 - $133.08 $265,283 - $369,829
2,779 New
2,779 $334,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.